Aerovate Therapeutics Price to Free Cash Flow Ratio 2020-2025 | JBIO
Historical price to free cash flow ratio values for Aerovate Therapeutics (JBIO) since 2020.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Aerovate Therapeutics Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2025-05-02 |
12.24 |
|
0.07 |
| 2025-03-31 |
85.60 |
$182.61 |
0.47 |
| 2024-12-31 |
90.38 |
$-87.40 |
0.00 |
| 2024-09-30 |
71.28 |
$-95.58 |
0.00 |
| 2024-06-30 |
56.61 |
$-92.84 |
0.00 |
| 2024-03-31 |
1008.47 |
$-358.48 |
0.00 |
| 2023-12-31 |
771.78 |
$-75.85 |
0.00 |
| 2023-09-30 |
462.80 |
$-74.68 |
0.00 |
| 2023-06-30 |
584.89 |
$-72.08 |
0.00 |
| 2023-03-31 |
687.89 |
$-64.39 |
0.00 |
| 2022-12-31 |
999.26 |
$-56.37 |
0.00 |
| 2022-09-30 |
565.45 |
$-92.64 |
0.00 |
| 2022-06-30 |
533.05 |
$1,029.32 |
0.52 |
| 2022-03-31 |
625.14 |
$-86.89 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.008B |
$0.000B |
|
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
|
